Interferon-deficient tumor cells

Interferon-deficient tumor cells represent a specific oncogenic phenotype characterized by the loss or impairment of the Type I interferon (IFN-α/β) signaling pathway. This deficiency is a common immune evasion strategy employed by various cancers to avoid detection and destruction by the host immune system, as interferons normally play a critical role in activating cytotoxic T cells and Natural Killer cells (Zitvogel et al., 2015). While this loss provides a survival advantage against the immune system, it creates a unique therapeutic vulnerability: these cells are unable to mount an effective antiviral response. This susceptibility is the primary rationale behind the use of oncolytic viruses, which are engineered or naturally selected to selectively replicate within and destroy IFN-deficient cells while being cleared by the intact antiviral machinery of healthy cells (Stojdl et al., 2003). Therapeutic strategies targeting this phenotype include the administration of oncolytic viruses like Talimogene laherparepvec and the development of STING agonists to bypass or restore signaling pathways (Xia et al., 2016). Identifying these cells through biomarkers like JAK mutations or low interferon-stimulated gene (ISG) expression is crucial for patient selection in clinical settings (Gao et al., 2016).

Other names

IFN-deficient cancer cellsType I interferon-deficient tumor cellsInterferon signaling-defective tumor cellsIFN-non-responsive tumor cells

Selective oncolysis through the exploitation of defective antiviral Type I interferon signaling pathways, allowing for preferential viral replication and lysis within tumor cells.